Genedrive PLC Posting of annual report and notice of AGM (7706V)
06 December 2023 - 6:00PM
UK Regulatory
TIDMGDR
RNS Number : 7706V
Genedrive PLC
06 December 2023
genedrive plc
("genedrive" or the "Company")
Posting of Annual Report and Accounts and notice of AGM
genedrive plc (AIM: GDR), the point of care pharmacogenetic
testing company, announces that its 2023 Annual Report and Accounts
are now available on the Company's website
http://www.genedriveplc.com/investor-relations/company-reports.php
.
The Notice of the 2023 Annual General Meeting ("AGM") and hard
copies of the 2023 Annual Report and Accounts will be posted to
shareholders on or around 6 December 2023.
The Company's AGM will be held at 10am on 29 December 2023 at
46-48 Grafton Street, Manchester M13 9XX.
For further details please contact:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
Anna Dunphy +44 (0)7876 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a pharmacogenetic testing company developing
and commercialising a low cost, rapid, versatile, simple to use and
robust point of need pharmacogenetic platform for the diagnosis of
genetic variations. This helps clinicians to quickly access key
genetic information that will help them make the right choices over
the right medicine or dosage to use for an effective treatment.
Based in the UK, the Company is at the forefront of work on Point
of Care pharmacogenetics. Pharmacogenetics looks at how your
genetics impacts a medicines ability to work for you. Therefore by
using pharmacogenetics, medicines can be made safer and more
effective. The Company has launched its flagship product, the
Genedrive(R) MT-RNR1 ID Kit, which is a single-use disposable
cartridge which circumvents the requirement for cold chain
logistics by providing temperature stable reagent test kits for use
on their proprietary test platform. This test allows clinicians to
make a decision on antibiotic use within 26 minutes, ensuring vital
care is delivered with no negative impact on the patient
pathway.
The Company has a clear commercial strategy focused on
accelerating growth through maximising in-market sales, geographic
and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAQELFBXLLXFBF
(END) Dow Jones Newswires
December 06, 2023 02:00 ET (07:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024